The following planners and faculty have indicated (a) relevant financial relationship(s) with an ACCME-defined ineligible company, also known as a commercial interest.
All relevant financial relationships have been mitigated. All others in control of content have indicated no relevant financial relationship with an ACCME-defined commercial interest. All clinical content presented will be evidence-based and unbiased.
| Planners and Faculty Names | Individual’s Role in Activity | Name of Commercial Interest | Nature of Relationship |
| John Wade, MD | Planning committee | Amgen | Consulting – Honorarium Recieved |
| Novartis | Consulting – Honorarium Recieved | ||
| AbbVie | Consulting – Honorarium Recieved | ||
| Fresenius Kabi | Consulting – Honorarium Recieved | ||
| Sobi | Consulting – Honorarium Recieved | ||
| Jeff Peterson, MD | Speaker | Amgen | Honorarium, Royalties (Speaker Advisor, IP) |
| Johnson and Johnson | Honorarium (Speaker) | ||
| UCB | Honorarium (Speaker) | ||
| Sobi | Honorarium (Consulting) | ||
| Antoine Minier | Speaker | Celltrion | Honorarium (Speaker) |
| Jan Dutz, MD | Speaker | Eli Lilly | Grants |
| Johnson and Johnson | Grants (independent contractor), honorarium (speaker) | ||
| Astra Zeneca | Grants (independent contractor), honorarium (speaker) | ||
| AbbVie | Honorarium (speaker) | ||
| Amgen | Honorarium (speaker) | ||
| Bausch | Honorarium (speaker) | ||
| Bristol Myers Squibb | Honorarium (Speaker, Honorarium (Drug safety monitoring board) | ||
| Celltrion | Honorarium (Speaker) | ||
| Galderma | Honorarium (Speaker) | ||
| Leo | Honorarium (Speaker) | ||
| Marcy Bolster | Speaker | Genetech | Grant (co-investigator) |
| Mitsubishi | Grant (co-investigator) | ||
| Prometheus | Grant (co-investigator) | ||
| Medscape | Honorarium (Consultant) | ||
| Boehringer Ingelheim | Honorarium (Consultant) | ||
| Johnson & Johnson | Honorarium (Consultant) | ||
| Taylor & Francis | Book Editor | ||
| American Board of Int. Med | Chair, LKA Approval Committee | ||
| The Merck Manual | Book Chapter Author | ||
| Michael Byrne | Speaker | Dova Health Intelligence | Stakeholder, Founder |
| DIGITAL | Canadian Federal Grant Support | ||
| Michael Walsh | Speaker | Otsuka | Consultant, Steering Committee |
| GSK | Consultant, Steering Committee | ||
| Bayer | Consultant, Steering Committee | ||
| Visterra | Consultant | ||
| AstraZeneca/Alexion | Consultant, Steering Committee | ||
| Novartis | Consultant, Steering Committee | ||
| Hansa | Data Monitoring Board | ||
| Novo Nordisc | Adjudication Board | ||
| Mollie Carruthers | Speaker | AbbVie | Speaker,Consulting |
| Amgen | Consulting | ||
| Janessen | Consulting, Speaking | ||
| Sanofi | Clinical Trials | ||
| UCB | Speaker | ||
| Zenas | Clinical Trials | ||
| Pfizer | Consulting | ||
| Moshe Bressler | Speaker | Power | Independant Contractor (consulting fees) |
| Antonio Avina-Zubieta | Speaker | Novartis | Consulting |
| Roche | Consulting | ||
| Novartis | Independant Contractor (PI Clinical Trials) |